Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma

Imagem de Miniatura
Arquivos
art_GRAZIANI_Phase_II_study_of_paclitaxel_associated_with_lipid_2017.PDF (5.81 MB)
Citações na Scopus
31
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HUMANA PRESS INC
Autores
EYLL, Brigitte M. Van
FERNANDES JUNIOR, Hezio J.
Citação
MEDICAL ONCOLOGY, v.34, n.9, article ID 151, 7p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Ovarian cancer is often diagnosed at advanced stages, when poorly responsive to standard treatment. First-line treatment consists in schemes including cytoreductive surgery followed by adjuvant chemotherapy schemes with platinum and taxane derivatives. Second-line regimens are based on gemcitabine and liposomal doxorubicin. Third line is often not worthwhile because of the high toxicity with poor response to treatment. Previously, we showed that paclitaxel (PTX) carried in non-protein lipid core nanoparticles (LDE) resembling the chemical structure of LDL has remarkably reduced toxicity. Here, the hypothesis was tested whether PTX-LDE could safely benefit patients in third-line treatment setting. Fourteen women unresponsive to second-line chemotherapy for ovarian cancer, aged 61 +/- 10 years, clinical stage IV and TqNqM1, were included. PTX-LDE was administered at 175 mg/m(2), 3/3 week dose. Patients were submitted to clinical examinations before each chemotherapy cycle. Serum biochemistry and imaging examinations to monitor disease progression were performed. In total, 74 cycles of chemotherapy were done and, in all cycles, clinical or laboratorial toxicities were not observed. Median progression-free survival (PFS) was 3.0 months (95% CI 2.0-3.9). In four patients, PFS was >6 months and in 2 > 1 year. The unpreceded, striking absence of toxicity and consistently long PFS, compared to previous results, indicate that at least 4 among 14 patients had tumor arrest by the treatment and clear benefit of PTX-LDE at third-line setting. The absence of observable toxicity allows dose escalating to improve response to treatment, as perspective to be tested in the ensuing studies.
Palavras-chave
Ovarian cancer treatment, Solid lipid particles, Drug delivery and cancer, Drug targeting and cancer, LDL receptors
URI
https://observatorio.fm.usp.br/handle/OPI/21823
Referências
  1. Ades A, 2001, GYNECOL ONCOL, V82, P84, DOI 10.1006/gyno.2001.6203
  2. Arbuck SG, 1993, J NATL CANC I MONO, V15, P117
  3. Azevedo CHM, 2005, GYNECOL ONCOL, V97, P178, DOI 10.1016/j.ygyno.2004.12.015
  4. Feio DCA, 2017, INT J NANOMED, V12, P3827, DOI 10.2147/IJN.S129153
  5. Bodnar L, 2011, GYNECOL ONCOL, V123, P33, DOI 10.1016/j.ygyno.2011.06.019
  6. BROWN MS, 1984, SCI AM, V251, P58
  7. Bruchim I, 2013, EUR J OBSTET GYN R B, V166, P94, DOI 10.1016/j.ejogrb.2012.10.003
  8. Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
  9. Chiyoda T, 2010, EUR J GYNAECOL ONCOL, V31, P364
  10. Covens A, 2002, GYNECOL ONCOL, V85, P71, DOI 10.1006/gyno.2001.6552
  11. Dias MLN, 2007, CANCER CHEMOTH PHARM, V59, P105, DOI 10.1007/s00280-006-0252-3
  12. Engel J, 2002, EUR J CANCER, V38, P2435, DOI 10.1016/S0959-8049(02)00495-1
  13. Ferlay J., 2015, INT J CANCER, V136, pE359, DOI 10.1002/IJC.29210
  14. Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654
  15. Gubbi A, 2014, EXPERT REV ANTICANC, V14, P1105, DOI 10.1586/14737140.2014.956095
  16. Heintz A P, 2001, J Epidemiol Biostat, V6, P107
  17. Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992
  18. HO YK, 1978, BLOOD, V52, P1099
  19. Hong SH, 2015, GYNECOL ONCOL, V136, P212, DOI 10.1016/j.ygyno.2014.11.017
  20. Hungria VTM, 2004, CANCER CHEMOTH PHARM, V53, P51, DOI 10.1007/s00280-003-0692-y
  21. Jabir NR, 2012, INT J NANOMED, V7, P4391, DOI 10.2147/IJN.S33838
  22. Krishnamurthy S, 2015, BIOMATER SCI-UK, V3, P923, DOI 10.1039/c4bm00427b
  23. Latorre A, 2002, INT J ONCOL, V21, P179
  24. Liang XJ, 2010, METHODS MOL BIOL, V596, P467, DOI 10.1007/978-1-60761-416-6_21
  25. Maier-Lenz H, 1997, SEMIN ONCOL, V24, pS16
  26. Maranhao RC, 2002, CANCER CHEMOTH PHARM, V49, P487, DOI 10.1007/s00280-002-0437-3
  27. MARANHAO RC, 1992, BRAZ J MED BIOL RES, V25, P1003
  28. Maranhao RC, 2017, EXPERT OPIN DRUG DEL, V1, P1
  29. McLachlan J, 2016, EXPERT OPIN PHARMACO, V17, P995, DOI 10.1517/14656566.2016.1165205
  30. Nishio S, 2009, J CANCER RES CLIN, V135, P551, DOI 10.1007/s00432-008-0488-x
  31. Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934
  32. Parmar MKB, 2003, LANCET, V361, P2099
  33. Pignata S, 2015, LANCET ONCOL, V16, P561, DOI 10.1016/S1470-2045(15)70115-4
  34. Pinheiro KV, 2006, CANCER CHEMOTH PHARM, V57, P624, DOI 10.1007/s00280-005-0090-8
  35. Pires L, 2009, CANCER CHEMOTH PHARM, V63, P281, DOI 10.1007/s00280-008-0738-2
  36. Raber-Durlacher JE, 2000, SUPPORT CARE CANCER, V8, P366, DOI 10.1007/s005200050004
  37. Rodrigues DG, 2005, CANCER CHEMOTH PHARM, V55, P565, DOI 10.1007/s00280-004-0930-y
  38. Sabbatini P, 2008, GYNECOL ONCOL, V111, P455, DOI 10.1016/j.ygyno.2008.07.049
  39. Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
  40. Sleep D, 2015, EXPERT OPIN DRUG DEL, V12, P793, DOI 10.1517/17425247.2015.993313
  41. STRICKLAND DK, 1995, FASEB J, V9, P890
  42. Waite Carolyn L., 2012, Critical Reviews in Biomedical Engineering, V40, P21, DOI 10.1615/CritRevBiomedEng.v40.i1.20
  43. WEISS RB, 1990, J CLIN ONCOL, V8, P1263
  44. Zylberberg C, 2016, DRUG DELIV, V23, P3319, DOI 10.1080/10717544.2016.1177136

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03